Please login to the form below

Not currently logged in


This page shows the latest Momenta news and features for those working in and with pharma, biotech and healthcare.

Merck confirms sale of biosimilar division

Merck confirms sale of biosimilar division

All told, more than a dozen companies, including Amgen, Samsung Bioepis, Boehringer Ingelheim, Momenta Pharmaceuticals and Sandoz, are developing Humira biosimilars, which may be a factor behind Merck's decision to

Latest news

More from news
Approximately 3 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’ Sandoz a tilt at the

  • Deal Watch January 2017 Deal Watch January 2017

    625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.

  • Deal Watch January 2016 Deal Watch January 2016

    255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept)  . 245. Athersys/ Healios. Licence. Development and commercialisation

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    The LMWH pipeline includes three compounds: certoparin sodium (Embolex; Novartis), semuloparin (Visamerin; Sanofi) and adomiparin (Momenta Pharmaceuticals).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...